-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PH-762 in Merkel Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PH-762 in Merkel Cell Carcinoma Drug Details: PH-762 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PH-762 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PH-762 in Solid Tumor Drug Details: PH-762 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PH-762 in Metastatic Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PH-762 in Metastatic Melanoma Drug Details: PH-762 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PH-762 in Cutaneous Squamous Cell Carcinoma (cSCC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PH-762 in Cutaneous Squamous Cell Carcinoma (cSCC) Drug Details: PH-762 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PH-762 in Head And Neck Squamous Cell Carcinoma (HNSC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PH-762 in Head And Neck Squamous Cell Carcinoma (HNSC) Drug Details: PH-762 is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PH-762 in Head And Neck Cancer Squamous Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PH-762 in Head And Neck Cancer Squamous Cell Carcinoma Drug Details: PH-762 is under development for...
-
Company Profile
![]()
Phio Pharmaceuticals Corp – Company Profile
Phio Pharmaceuticals Corp (Phio Pharmaceuticals), formerly known as RXi Pharmaceuticals Corp, is a biotechnology company. The company discovers, develops and commercializes immuno-oncology therapeutics based RNAi platform to treat cancer. Its product pipeline includes PH-762, PH-894 and PH-804 for adoptive cell therapy, tumor microenvironment and intratumoral. Phio Pharmaceuticals also provides clinical trial services. Phio Pharmaceuticals offers products for the treatment of anti scarring, macular degeneration, retinoblastoma, and liver diseases. The company partners with academia, biotech, and large multi-national organizations for the...
Add to Basket -
Product Insights
![]()
Age Related Macular Degeneration Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Age Related Macular Degeneration Pipeline Drugs Market Report Overview Age related macular degeneration is the most common reason for vision loss in people aged above 50. It results in the depreciation of the macula which may lead to distorted or blurry central vision. The predisposing factors involved are age, smoking, sunlight, heredity, etc. Symptoms include the development of blind spots and hazy vision. The condition may be treated by photodynamic therapy, radiation therapy, and medication such as anti-angiogenic drugs. The...
-
Product Insights
![]()
Colon Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Colon Cancer Pipeline Drugs Market Overview Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools, and weight loss with...
-
Product Insights
![]()
Ovarian Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Ovarian Cancer Pipeline Products Market Report Overview Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, and changes in bowel habits, such as constipation, loss of appetite, and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy, and radiation...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.